MediPharm Labs Corp.
LABS.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 8.60M | 7.18M | 7.56M | 7.25M | 6.71M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.60M | 7.18M | 7.56M | 7.25M | 6.71M |
| Cost of Revenue | 5.84M | 4.83M | 4.98M | 4.86M | 3.30M |
| Gross Profit | 2.77M | 2.36M | 2.58M | 2.38M | 3.41M |
| SG&A Expenses | 3.09M | 4.00M | 4.28M | 4.38M | 2.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -90.70K | 150.30K | 30.70K | -138.00K | 40.40K |
| Total Operating Expenses | 8.88M | 9.07M | 9.33M | 9.16M | 5.80M |
| Operating Income | -276.50K | -1.89M | -1.77M | -1.91M | 910.70K |
| Income Before Tax | -1.23M | -2.03M | -1.89M | -2.68M | -2.25M |
| Income Tax Expenses | -- | -- | -- | -- | -200.70K |
| Earnings from Continuing Operations | -1.23M | -2.03M | -1.89M | -2.68M | -2.05M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.23M | -2.03M | -1.89M | -2.68M | -2.05M |
| EBIT | -276.50K | -1.89M | -1.77M | -1.91M | 910.70K |
| EBITDA | 112.90K | -1.51M | -1.25M | -1.34M | 1.36M |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 411.83M | 411.07M | 404.78M | 403.68M | 377.79M |
| Average Diluted Shares Outstanding | 411.83M | 411.07M | 404.78M | 403.68M | 377.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |